{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:50Z","timestamp":1787009030471,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["UM1AI104681"],"award-info":[{"award-number":["UM1AI104681"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Use of anti-carbapenem-resistant Enterobacterales (anti-CRE) agents such as ceftazidime\/avibactam has been associated with improved clinical outcome in cohorts that primarily include patients infected with CRE that are resistant to meropenem (MCRE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To clarify whether patients with CRE resistant to ertapenem but susceptible to meropenem (ertapenem-only-resistant Enterobacterales; EORE) benefit from therapy with anti-CRE agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients treated for CRE infection in hospitals in the USA between 2016 and 2019 and enrolled in the CRACKLE-2 study were included. The primary outcome was the desirability of outcome ranking (DOOR) assessed at 30\u2005days after index cultures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The EORE group included 213 patients and the MCRE group included 643. The demographics were similar between the groups except for the patients\u2019 race and origin before admission. The MCRE group received anti-CRE agents for definitive therapy significantly more frequently compared with the EORE group (30% versus 5% for ceftazidime\/avibactam). We did not observe a significant difference between the groups in the adjusted DOOR probability of a more desirable outcome for a randomly selected patient in the EORE group compared with the MCRE group (52.5%; 95% CI, 48.3%\u201356.7%). The MCRE group had a similar proportion of patients who died at 30\u2005days (26% versus 21%) and who were discharged to home (29% versus 40%), compared with the EORE group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with clinical EORE infection rarely received anti-CRE agents, but attained similar outcomes compared with patients with MCRE infection. The findings support current IDSA treatment guidance for meropenem- or imipenem-based therapy for treatment of EORE infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae186","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T11:55:49Z","timestamp":1717070149000},"page":"1929-1937","source":"Crossref","is-referenced-by-count":6,"title":["Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1801-6628","authenticated-orcid":false,"given":"Gregory","family":"Weston","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine , Bronx, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhigya","family":"Giri","sequence":"additional","affiliation":[{"name":"The Biostatistics Center, George Washington University , Rockville, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Komarow","sequence":"additional","affiliation":[{"name":"The Biostatistics Center, George Washington University , Rockville, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhao","family":"Ge","sequence":"additional","affiliation":[{"name":"The Biostatistics Center, George Washington University , Rockville, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri R","family":"Baum","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Abbenante","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8532-0887","authenticated-orcid":false,"given":"Jason C","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Temple University School of Pharmacy , Philadelphia, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9811-6260","authenticated-orcid":false,"given":"Jesse T","family":"Jacob","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-1732","authenticated-orcid":false,"given":"Keith S","family":"Kaye","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell , Manhasset, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Charles","family":"Huskins","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-4898","authenticated-orcid":false,"given":"Marcus","family":"Zervos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Henry Ford Hospital , Detroit, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Herc","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Henry Ford Hospital , Detroit, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-4141","authenticated-orcid":false,"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN , USA"},{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic , Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-3227","authenticated-orcid":false,"given":"David","family":"Van Duin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of North Carolina , Chapel Hill, NC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-2525","authenticated-orcid":false,"given":"Yohei","family":"Doi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Pittsburgh School of Medicine , Pittsburgh, PA , USA"},{"name":"Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine , Aichi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"2024073123523915000_dkae186-B1","author":"Centers for Disease Control and Prevention"},{"key":"2024073123523915000_dkae186-B2","doi-asserted-by":"crossref","first-page":"e02349-16","DOI":"10.1128\/AAC.02349-16","article-title":"Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States","volume":"61","author":"Satlin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123523915000_dkae186-B3","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","article-title":"Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment","volume":"17","author":"Zarkotou","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2024073123523915000_dkae186-B4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2024073123523915000_dkae186-B5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1586\/14787210.2013.836057","article-title":"Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections","volume":"11","author":"Viale","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024073123523915000_dkae186-B6","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/AAC.06268-11","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","author":"Qureshi","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123523915000_dkae186-B7","doi-asserted-by":"crossref","first-page":"00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123523915000_dkae186-B8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024073123523915000_dkae186-B9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2024073123523915000_dkae186-B10","first-page":"02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123523915000_dkae186-B11","doi-asserted-by":"crossref","first-page":"02101-17","DOI":"10.1128\/AAC.02101-17","article-title":"Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates","volume":"62","author":"Giddins","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123523915000_dkae186-B12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/jac\/dkz026","article-title":"Ceftazidime\/avibactam resistance associated with L169P mutation in the omega loop of KPC-2","volume":"74","author":"Hemarajata","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024073123523915000_dkae186-B13","doi-asserted-by":"crossref","first-page":"01111-19","DOI":"10.1128\/AAC.01111-19","article-title":"Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity","volume":"63","author":"Mueller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123523915000_dkae186-B14","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/jac\/dkz330","article-title":"Emergence of ceftazidime\/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo","volume":"74","author":"Gottig","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024073123523915000_dkae186-B15","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/jac\/dkz125","article-title":"Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime\/avibactam","volume":"74","author":"Papadimitriou-Olivgeris","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024073123523915000_dkae186-B16"},{"key":"2024073123523915000_dkae186-B17","first-page":"175","article-title":"Effect of varying federal definitions on prevalence and characteristics associated with carbapenem-resistant Enterobacteriaceae in veterans with spinal cord injury","volume-title":"Am J Infect Control","author":"Fitzpatrick","year":"2019"},{"key":"2024073123523915000_dkae186-B18","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijantimicag.2018.03.020","article-title":"Role of association of OmpK35 and OmpK36 alteration and blaESBL and\/or blaAmpC genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae","volume":"52","author":"Hamzaoui","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2024073123523915000_dkae186-B19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cll.2017.01.005","article-title":"Carbapenem-resistant Enterobacteriaceae","volume":"37","author":"Iovleva","year":"2017","journal-title":"Clin Lab Med"},{"key":"2024073123523915000_dkae186-B20","doi-asserted-by":"crossref","first-page":"ofab643","DOI":"10.1093\/ofid\/ofab643","article-title":"Distinctive features of ertapenem-mono-resistant carbapenem-resistant Enterobacterales in the United States: a cohort study","volume":"9","author":"Adelman","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024073123523915000_dkae186-B21","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024073123523915000_dkae186-B22","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam versus meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2024073123523915000_dkae186-B23","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2024073123523915000_dkae186-B24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(21)00399-6","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024073123523915000_dkae186-B25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2307\/2531493","article-title":"Distribution-free confidence intervals for a parameter of Wilcoxon-Mann-Whitney type for ordered categories and progressive censoring","volume":"45","author":"Halperin","year":"1989","journal-title":"Biometrics"},{"key":"2024073123523915000_dkae186-B26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciw741","article-title":"Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia","volume":"64","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024073123523915000_dkae186-B27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dkz501","article-title":"Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae","volume":"75","author":"Hayakawa","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024073123523915000_dkae186-B28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024073123523915000_dkae186-B29","doi-asserted-by":"crossref","first-page":"e1157","DOI":"10.1093\/cid\/ciac692","article-title":"Improving traditional registrational trial end points: development and application of a desirability of outcome ranking end point for complicated urinary tract infection clinical trials","volume":"76","author":"Howard-Anderson","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1929\/58689067\/dkae186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1929\/58689067\/dkae186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T02:19:03Z","timestamp":1722478743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/8\/1929\/7691347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,6,12]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae186","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,6,12]]}}}